Introduction to the price of generic drugs of Adagrasib (Krazati) and the purchasing channels of various versions of the drug

Adagrasib (Krazati) is a KRAS G12C targeted inhibitor, mainly used to treat malignant tumors such as non-small cell lung cancer carrying KRAS G12C mutations. As another approved KRAS inhibitor after sotoracib, adagrasiib has shown good response and disease control rates in multiple international clinical trials, providing a new option for patients with KRAS mutations who lacked effective treatments in the past. At present, the drug has been approved in the United States and other countries, but it has not yet been officially launched in China. Therefore, domestic patients are temporarily unable to purchase it directly through local formal channels.

In the U.S. market, adagrasib is an innovative targeted drug and is relatively expensive. According to public price information, the price of each box of the American version of the original drug is as high as hundreds of thousands of yuan, which is a heavy burden for ordinary patients. Since patients with KRAS G12C mutations often require long-term medication maintenance treatment, high drug expenditures have become a real problem faced by many patients, which has also prompted many people to pay attention to the availability of other versions of drugs overseas.

At present, what is attracting more attention is the Laotian generic version of adagrasibu. Its ingredients are basically the same as the original drug, but the price is much lower than the original version in the United States. The price of each box of the Lao version is about more than 3,000 yuan, and the economic burden is relatively controllable. For patients who need long-term medication, this price advantage greatly improves the accessibility and compliance of medication. Although the clinical verification data of generic drugs is not as comprehensive as that of original drugs, most versions have passed bioequivalence studies and still have certain guarantees in terms of efficacy and safety.

Since adagrasib has not yet been marketed in the country, patients who need medicine mainly rely on overseas channels to obtain it. On the one hand, formal purchasing can be carried out through some international pharmacies or cross-border medical institutions; on the other hand, some patients also choose generic drug channels in countries such as Laos. When choosing, you should try your best to use reliable platforms or formal channels to avoid purchasing drugs from unknown sources or counterfeit drugs. At the same time, it is recommended to use this drug under the guidance of a professional doctor, and conduct regular monitoring of efficacy and safety to ensure maximum benefits and reduce risks.

Reference link:https://www.drugs.com